Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Umang Swami

Showing results (141-150 of 171) with videos related to

Pageof 18
Sort By:
JAMA Network Open|October 15, 2024
Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of the SPARTAN Randomized Clinical TrialSoumyajit Roy, Shawn Malone, Kevin Wing, et al.
Journal for Immunotherapy of Cancer|August 16, 2023
Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burdenVaia Florou, Charalampos S Floudas, Asaf Maoz, et al.
The Oncologist|March 5, 2026
Molecular Landscape of Prostate Cancers with Clival MetastasesPornlada Likasitwatanakul, Steven M Blinka, Jabra G Zarka, et al.
Journal for Immunotherapy of Cancer|March 18, 2025
Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)Gliceida M Galarza Fortuna, Daniel Grass, Benjamin L Maughan, et al.
The Oncologist|March 11, 2022
Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate CancerMeredith N Freeman, Albert Jang, Jason Zhu, et al.
Research Square|July 3, 2023
Response to high dose ipilimumab plus temozolomide after progression on standard or low dose ipilimumab in advanced melanoma: a retrospective analysisJulie Williamson, Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics-Bankowski, et al.
The Prostate|April 1, 2024
Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive settingGeorges Gebrael, Chadi Hage Chehade, Nicolas Sayegh, et al.
European Urology|March 14, 2024
Effect of Prior Prostate Directed Local Therapy on Response to Apalutamide in Metastatic Hormone Sensitive Prostate Cancer: A Secondary Analysis of the TITAN StudySoumyajit Roy, Fred Saad, Shawn Malone, et al.
JCO Oncology Practice|June 18, 2026
Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO GuidelineChristina M Lockwood, Hans J Messersmith, Annette S Kim, et al.
Clinical Proteomics|April 18, 2025
Circulatory prostate cancer proteome landscapes and prognostic biomarkers in metastatic castrate resistant prostate cancerHyejung Lee, Jincheng Shen, Muhammad Zaki Fadlullah, et al.
Pageof 18

Showing results (141-150 of 171) with videos related to

Sort By:
Pageof 18
JAMA Network Open|October 15, 2024
Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of the SPARTAN Randomized Clinical TrialSoumyajit Roy, Shawn Malone, Kevin Wing, et al.
Journal for Immunotherapy of Cancer|August 16, 2023
Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burdenVaia Florou, Charalampos S Floudas, Asaf Maoz, et al.
The Oncologist|March 5, 2026
Molecular Landscape of Prostate Cancers with Clival MetastasesPornlada Likasitwatanakul, Steven M Blinka, Jabra G Zarka, et al.
Journal for Immunotherapy of Cancer|March 18, 2025
Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)Gliceida M Galarza Fortuna, Daniel Grass, Benjamin L Maughan, et al.
The Oncologist|March 11, 2022
Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate CancerMeredith N Freeman, Albert Jang, Jason Zhu, et al.
Research Square|July 3, 2023
Response to high dose ipilimumab plus temozolomide after progression on standard or low dose ipilimumab in advanced melanoma: a retrospective analysisJulie Williamson, Muhammad Zaki Hidayatullah Fadlullah, Magdalena Kovacsovics-Bankowski, et al.
The Prostate|April 1, 2024
Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive settingGeorges Gebrael, Chadi Hage Chehade, Nicolas Sayegh, et al.
European Urology|March 14, 2024
Effect of Prior Prostate Directed Local Therapy on Response to Apalutamide in Metastatic Hormone Sensitive Prostate Cancer: A Secondary Analysis of the TITAN StudySoumyajit Roy, Fred Saad, Shawn Malone, et al.
JCO Oncology Practice|June 18, 2026
Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO GuidelineChristina M Lockwood, Hans J Messersmith, Annette S Kim, et al.
Clinical Proteomics|April 18, 2025
Circulatory prostate cancer proteome landscapes and prognostic biomarkers in metastatic castrate resistant prostate cancerHyejung Lee, Jincheng Shen, Muhammad Zaki Fadlullah, et al.
Pageof 18